Clinical Trial: Study of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone Mass

U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07806331) titled 'Study of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone Mass' on Aug. 20.

Brief Summary: This is a randomized, double-blind, placebo- and active-controlled Phase II study evaluating the efficacy and safety of TST002 injection (a humanized monoclonal antibody) in postmenopausal women with osteoporosis or low bone mass, aged 45-80 years.

Approximately 110 participants will be randomized 1:1:1:1:1 (stratified by baseline BMD T-score) to one of five arms: TST002 400 mg every 8 weeks (Q8W), TST002 800 mg Q8W, TST002 1200 mg every 12 weeks (Q12W), placebo, or open-label denosumab 60 mg subcutaneously every 24 week...